Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 1996

View Archived Issues

Therapeutically active nicotinic acid esters described by Scotia

Bayer describes new ASA derivatives

New lipophilic drug delivery agents from Scotia

Radiopharmaceutical agents from CIS Bio International

Mercian reports new antitumor anthracycline

Antineoplastic anthracycline antibiotic disclosed by Mercian

Innapharma reports novel antidepressant

DuPont Merck developing atypical antipsychotic

DuPont Merck reports ester prodrugs for glaucoma

NK1 receptor antagonist synthesized by RPR

5-LO inhibitor under evaluation at SKB

HemispheRx and Temple University enter new agreement for Oragen products

MedImmune receives patent coverage for RespiGam

Antex to be issued patent covering H. influenzae proteins

Prostate cancer gene therapy trial commences

The role of host factors in HIV pathogenesis

Innovative NRT recommended for approval

New insights into migraine pathology

Carrington Laboratories and Recordati reach licensing agreement

Positive phase II results with RMP-7/carboplatin

Clinical trial on OXiGENE's Sensamide/Neu-Sensamide nearing completion

Medtronic and Orphan Medical to develop intrathecal clonidine

Circularly permuted proteins and fusion proteins available for licensing

Licensees sought for vector for polynucleotide vaccines

Heterologous vectors for boosting antitumor immunity available for licensing

Licenses offered for marker in the human iNOS gene promoter region

Knoll licenses technology for use in cardiovascular research

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...